top of page
AAO 2026: RETINA DRUG DELIVERY & NEW TARGETS SHOWCASE
Moderators: Allen C. Ho, MD, Retina Program Director; Rachel Huckfeldt, MD, PhD, Program Committee ; Mark Humayun, MD, PhD, Director, USC Ginsburg Institute for Biomedical Therapeutics; and John Trein, MD, Therapeutic Lead, Posterior, Ora
Rooms: 252-254
Start | Company | Presenter |
|---|---|---|
1:00 PM | Introduction | Allen C. Ho, MD |
1:02 PM | Nanoscope Therapeutics | Paul Hallen, Chief Operating Officer |
1:07 PM | AAVantgarde | Natalia Misciattelli, PhD, CEO |
1:12 PM | Ocugen | Arun Upadhyay, PhD, Chief Scientific Officer, Head of R & D |
1:17 PM | Discussion | |
1:25 PM | Adverum Biotechnologies | Star Seyedkazemi, PharmD, Chief Development Officer |
1:30 PM | Kriya Therapeutics | Shankar Ramaswamy, MD, Co-Founder & CEO |
1:35 PM | Discussion | |
1:43 PM | Optigo Biotherapeutics | Houman Hemmati, MD, PhD, Co-founder & Chief Medical Officer |
1:48 PM | Valitor | Greg Kunst, MBA, CEO |
1:.53 PM | Re-Vana Therapeutics | Jim Mcllroy, PhD, MBA, VP, Quality |
1:58 PM | Discussion | |
2:06 PM | MingMed Biotechnology | Liza Ko, Chief Financial Officer |
2:11 PM | InGel Therapeutics | Greg Kunst, MBA, CEO |
2:16 PM | Neurotech Pharmaceuticals, Inc. | Rich Small, CEO |
2:21 PM | Discussion | |
2:29 PM | Conclusion | |
2:30 PM | End of Session |
Anchor 1
bottom of page